FDA accepts Surfaxin response

Discovery Labs (DSCO) rose $0.63 (11%) to $6.41 on 1.7 million shares on Friday after FDA accepted as complete the company's Oct. 5 response to a February approvable letter for Surfaxin lucinactant to...